151751-Najiba-Chargi

329 Systemic therapy: skeletal muscle mass and functional outcomes Appendix 3. (Continued). RT CRT (cetuximab) CRT (cisplatin) t 0 n = 42 t 1 n = 39 t 2 n = 28 t 0 n = 17 t 1 n = 17 t 2 n = 11 t 0 n = 49 t 1 n = 43 t 2 n = 32 Communication 0 (0-50) 0 (0-38) 0 (0-25) 0 (0-50) 25 (0-75) 7 (0-25) 0 (0-75) 0 (0-63) 0 (0-63) Mental health 0 (0-69) 0 (0-25) 0 (0-30) 0 (0-25) 25 (0-100) 20 (0-25) 0 (0-75) 3 (0-60) 0 (0-45) Social functioning 0 (0-40) 0 (0-40) 0 (0-30) 0 (0-25) 25 (0-60) 0 (0-25) 0 (0-70) 0 (0-50) 0 (0-30) Symptoms 11 (0-79) 15 (0-36) 13 (0-27) 5 (0-21) 14 (5-52) 15 (0-23) 7 (0-48) 20 (0-48) 14 (0-41) Total score 1 (0-67) 6 (0-41) 2 (0-31) 3 (0-28) 21 (0-77) 25 (0-32) 10 (0-69) 18 (0-57) 10 (0-43) SWAL-QOL ≥ 14 No 19 (68) 15 (68) 21 (91) 12 (86) 5 (39) 3 (38) 21 (58) 15 (47) 14 (64) Yes 9 (32) 7 (32) 2 (9) 2 (14) 8 (62) 5 (63) 15 (42) 17 (53) 8 (36) Unknown 14 17 5 3 4 3 12 11 10 Secondary outcomes Feeding tube No 41 (98) 39 (100) 28 (100) 17 (100) 15 (88) 11 (100) 48 (98) 39 (91) 32 (100) Yes NGT 1 (2) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) Yes PRG 0 (0) 0 (0) 0 (0) 0 (0) 2 (12) 0 (0) 1 (2) 4 (9) 0 (0) Unknown 0 0 0 0 0 0 0 0 0 Pneumonia No 40 (95) 34 (97) 27 (96) 16 (94) 16 (94) 10 (91) 42 (98) 40 (98) 30 (97) Yes 2 (5) 1 (3) 1 (4) 1 (6) 1 (6) 1 (9) 1 (2) 1 (2) 1 (3) Unknown 0 4 0 0 0 0 6 2 1 NB: Not all percentages sum up exactly to 100%due to rounding.Abbreviations: FOIS = functional oral intake scale, t0 = pretreatment, t1 = six months after treatment, t2 = twelve months after treatment. 17